How did Centessa Pharmaceuticals plc ADR (CNTA) surprise investors with its report?

A share price of Centessa Pharmaceuticals plc ADR [CNTA] is currently trading at $17.60, up 5.07%. An important factor to consider is whether the stock is rising or falling in short-term value. The CNTA shares have gain 3.29% over the last week, with a monthly amount glided 10.00%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

From an analyst’s perspective:

Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] stock has seen the most recent analyst activity on September 20, 2024, when Morgan Stanley upgraded its rating to a Overweight and also boosted its price target to $26 from $11. Previously, B. Riley Securities started tracking the stock with Buy rating on September 19, 2024, and set its price target to $33. On July 18, 2024, Oppenheimer initiated with a Outperform rating and assigned a price target of $14 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $11 on November 15, 2023. Morgan Stanley upgraded its rating to a Equal-Weight and raised its price target to $8 on October 26, 2023. In a note dated June 12, 2023, Guggenheim initiated an Buy rating and provided a target price of $9 on this stock.

Centessa Pharmaceuticals plc ADR experienced fluctuations in its stock price throughout the past year between $6.65 and $18.97. Currently, Wall Street analysts expect the stock to reach $23.25 within the next 12 months. Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] shares were valued at $17.60 at the most recent close of the market. An investor can expect a potential return of 32.1% based on the average CNTA price forecast.

Analyzing the CNTA fundamentals

Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -23.43%, Pretax Profit Margin comes in at -22.95%, and Net Profit Margin reading is -23.37%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.52 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.17.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.76 points at the first support level, and at 15.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.28, and for the 2nd resistance point, it is at 18.96.

Ratios To Look Out For

To put it in perspective, the Current Ratio for Centessa Pharmaceuticals plc ADR [NASDAQ:CNTA] is 21.52. On the other hand, the Quick Ratio is 21.52, and the Cash Ratio is 14.96. Considering the valuation of this stock, the price to sales ratio is 335.34, the price to book ratio is 4.64.

Transactions by insiders

Recent insider trading involved Bush Tia L, Chief Technology & Quality Ofc, that happened on Dec 17 ’24 when 17813.0 shares were sold. Chief Technology & Quality Ofc, Bush Tia L completed a deal on Dec 16 ’24 to sell 9611.0 shares. Meanwhile, General Counsel HUSSAIN IQBAL J sold 77705.0 shares on Dec 16 ’24.

Related Posts